Tirzepatide leads near-term, Retatrutide targets Class III, Foundayo expands maintenance—see 2030 sales & $1,300 PT.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results